Bristol-Myers Squibb and Oncolys BioPharma, a privately-held biotechnology company based in Japan, have signed a definitive agreement under which BMS will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, oral nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV. Oncolys is eligible to receive as much as $286 million including upfront, development, regulatory, and sales milestone payments, as well as royalties o...